Garth Lees-Rolfe
Directeur Financier/CFO chez INHIBIKASE THERAPEUTICS, INC.
Fortune : - $ au 31/05/2024
Postes actifs de Garth Lees-Rolfe
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| INHIBIKASE THERAPEUTICS, INC. | Directeur Financier/CFO | 31/03/2024 | - |
| Corporate Officer/Principal | 01/11/2022 | 31/03/2024 |
Historique de carrière de Garth Lees-Rolfe
Anciens postes connus de Garth Lees-Rolfe
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| F-STAR THERAPEUTICS, INC. | Corporate Officer/Principal | 01/12/2021 | 01/11/2022 |
Formation de Garth Lees-Rolfe
| Queensland University of Technology | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 2 |
| Australie | 2 |
| Royaume-Uni | 2 |
Opérationnelle
| Corporate Officer/Principal | 2 |
| Director of Finance/CFO | 1 |
| Undergraduate Degree | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| INHIBIKASE THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
F-star Therapeutics, Inc.
 F-star Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
- Bourse
- Insiders
- Garth Lees-Rolfe
- Expérience
